Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 12/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519557 | 0.89 | MTOR (0.55) | PDE4APDE4BPDE4CPDE4DMOK | |
| SCHEMBL823729 | 0.88 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DMOK | |
| SCHEMBL3765184 | 0.85 | NOS1 (0.64) | MOKJAK2JAK3MTORPIK3CA | |
| SCHEMBL4528710 | 0.80 | PIK3CD (0.54) | PDE4APDE4BPDE4CPDE4DMTOR | |
| SCHEMBL4523686 | 0.79 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DMOK | |
| SCHEMBL4531681 | 0.79 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DMOK | |
| SCHEMBL3765421 | 0.79 | NOS1 (0.63) | JAK2JAK3MTORPIK3CAPIK3CG | |
| SCHEMBL3765436 | 0.79 | NOS1 (0.63) | JAK2JAK3MTORPIK3CAPIK3CG | |
| SCHEMBL4519946 | 0.78 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DJAK2 | |
| SCHEMBL4101991 | 0.78 | NOS1 (0.52) | PDE4APDE4BPDE4CPDE4DMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | PDE4A 1370/4885PDE4B 1438/4885PDE4C 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.